Skip to main content
Back to companies
Cambridge, Massachusetts, United StatesFounded 2014111+ employeesXFOR
$760.6M raisedIPO· last: post ipo equity (Oct 2025)· 13 rounds
Backed by(23 investors)
New Enterprise Associates · LeadCoastlands Capital · LeadHercules Capital · LeadAcorn Bioventures · LeadCormorant Asset Management · LeadLumira Ventures · Lead+9 more
5 layoff events · Last: Nov 2025

We are a fully integrated, commercial-stage biopharmaceutical company driving progress for people living with rare immune disorders. We listen to people whose challenges have been long overlooked, understand their needs, and develop solutions to their most urgent and critical health concerns. Our FDA-approved medication XOLREMDI® (mavorixafor) is commercially available in the U.S. in its first indication. We are evaluating mavorixafor in additional potential indications, and have an ongoing global, pivotal Phase 3 clinical trial for its use in chronic neutropenia. Our corporate headquarters is in Boston, Massachusetts.

Founders

Skip jobs list

Open Positions at X4 Pharmaceuticals (0 Jobs)

No open positions at the moment.
Try adjusting your filters or browse all jobs
Browse All Jobs